23andMe Eyes $1.7B Valuation With $200M Round

23andMe Eyes $1.7B Valuation With $200M Round
By 23andMe [Public domain], via Wikimedia Commons

Genetics company 23andMe is in the process of raising about $200 million, as first reported by TechCrunch. The funding will reportedly be led by Sequoia and come with a $1.7 billion valuation. 23andMe offers genetic services that provide users with information about their ancestry and personal health.

News of the round comes about five months after 23andMe scored a big win for one of its products, with the US Food and Drug Administration approving a saliva-based test that assesses a person’s genetic risk for Alzheimer’s, Parkinson’s and eight other diseases. Since it was founded in 2006, the Bay Area biotech has raised hundreds of millions—but co-founder and CEO Anne Wojcicki is said to be in no rush to IPO. Here’s a look at the company’s equity funding history:

May 2007: $9M funding | $45M valuation

Alkeon: Big Tech Is Only Just Getting Started

TechnologyThe ACAP Strategic Fund's managers see a "significant scarcity of attractive asset allocation choices globally," but also a strong environment for fundamental stock picking. Q2 2021 hedge fund letters, conferences and more According to a copy of the fund's second-quarter investor update, which ValueWalk has been able to review, its managers currently hold a balanced Read More

Dec. 2009: $27.8M | $138.9M

Jan. 2011: $31M | $179M

Dec. 2012: $58M | $288.7M

Oct. 2015: $115M | $1.1B

Want more info on 23andMe? Check out its free profile.

Article by PitchBook

No posts to display